Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sawai Pharmaceutical Co. Ltd.

www.sawai.co.jp

Latest From Sawai Pharmaceutical Co. Ltd.

Sawai Sets Upsher-Smith $50m+ Target For Former Reddy’s Brands

Sawai believes the Zembrace and Tosymra sumatriptan brands acquired by its US operation Upsher-Smith could within the next three years bring in more than $50m in annual sales.

Value-Added Medicines Sales & Earnings

Sawai Eyes Global Position Helped By Growth In Japan And Upsher-Smith – But No Biosimilars

In an exclusive interview, the president of Japan’s largest generics company relates his strategy for success, including internal expertise in intellectual property challenges and staying away from biosimilars. US acquisition Upsher-Smith will meanwhile provide the foundation for overseas growth.

Japan Business Strategies

Sawai Eyes Global Position Helped by Japan Growth And Upsher-Smith – But No Biosimilars

In an exclusive interview, the president of Japan’s largest generics company relates his strategy for success, including internal expertise in intellectual property challenges and staying away from biosimilars. US acquisition Upsher-Smith will meanwhile provide the foundation for overseas growth.

Japan Business Strategies

Sawai's Upsher-Smith Snaps Up Dr Reddy’s Branded Migraine Assets

Upsher-Smith has acquired US and other territory rights to two specialty product assets of Dr Reddy’s, which appears to be tweaking the commercialization approach of its proprietary products business.

Commercial Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Metabolic Disorders
  • Alias(es)
  • SAWAI PHARMACEUTICALS LTD.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Sawai Pharmaceutical Co. Ltd.
  • Senior Management
  • Mitsuo Sawai, Pres.
  • Contact Info
  • Sawai Pharmaceutical Co. Ltd.
    Phone: (81) 6 6105 5729
    5-2-30, Miyahara
    Yodogawa-Ku
    Osaka, 532-0003
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register